Adults and Teens Need Vaccines Too

08.18.20

Most vaccination programs focus on protecting children, even though the major burden of vaccine-preventable diseases is in adults.

Read more

Professor Gordon Dougan Receives the 2020 Albert B. Sabin Gold Medal; Sabin Vaccine Institute’s New Rising Star Award Presented to Dr. Katherine E. Gallagher

Submitted by Samia Kemal on

Sabin today announced that it has awarded its annual Albert B. Sabin Gold Medal to Gordon Dougan, FRS, professor in the Department of Medicine and the Cambridge Institute for Therapeutic Immunology and Infectious Disease at the University of Cambridge. Sabin also presented the inaugural Rising Star Award to Katherine E. Gallagher, MSc, PhD, assistant professor of epidemiology at the London School of Hygiene and Tropical Medicine.

How Do Vaccines Work?

08.04.20

Vaccines are one of the greatest achievements in modern medical history. More lives have been saved thanks to vaccines than any other medical advance in recent years.

Read more

Sabin's President of Global Immunization Dr. Bruce Gellin Testifies at House Briefing on Approval Processes for Safe, Effective COVID-19 Vaccine

Submitted by Samia Kemal on

Bruce Gellin, M.D., M.P.H., president of Global Immunization at the Sabin Vaccine Institute (Sabin) and former Deputy Assistant Secretary for Health and Director of the National Vaccine Program Office at the U.S. Department of Health and Human Services (HHS), testified on July, 14, 2020, at the House Subcommittee on Economic and Consumer Policy’s briefing entitled “Guardrails to Ensure a Safe and Effective COVID-19 Vaccine.”

Sabin Vaccine Institute Signs CHANGE Letter; Rejecting White House Decision to Pull Funding from WHO

Submitted by Samia Kemal on

WASHINGTON, D.C. — In response to the harmful and impulsive decision to withdraw funds from the World Health Organization (WHO), the Sabin Vaccine Institute (Sabin) joins the Center for Health and Gender Equity (CHANGE) and more than 65 other non-governmental organizations and global health institutions in an official letter of solidarity to WHO Director-General Dr. Tedros Adhanom Ghebreyesus and WHO staff worldwide.

Sabin Vaccine Institute’s Boost Community Prepares Immunization Professionals to Lead During the COVID-19 Crisis

Submitted by Samia Kemal on

WASHINGTON D.C. – Amid the evolving global challenges posed by the novel coronavirus pandemic, immunization professionals must now grapple with deploying routine immunization services in a daunting and ever-shifting landscape. To strengthen immunization professionals’ ability to navigate the complex challenges of their work, Sabin launched the Boost Community (Boost), a global network dedicated to serving immunization professionals, supported by a grant from the Bill & Melinda Gates Foundation.

Our Commitment to Anti-Racism

Sabin's picture Submitted by Sabin on

In our strongest and most unified voice, the Sabin Vaccine Institute condemns racism. Dr. Albert Sabin was a great scientist, and importantly his work led him to fight for equality so that all children everywhere – regardless of race, religion, nationality, gender or socioeconomic status – received his lifesaving polio vaccine.

Amid COVID-19 Vaccine Race, Sabin Vaccine Institute and the Aspen Institute Release Report on Vaccine Hesitancy; A Call to Improve Vaccine Acceptance

Submitted by Liz Powell on

WASHINGTON, D.C. -- As the COVID-19 vaccine race accelerates, experts recognize that the challenge will not end with the development of a vaccine. The extraordinary effort to make a vaccine available across the globe will only be effective if the majority of people achieve immunity through vaccination.

BARDA Provides the Sabin Vaccine Institute with an Additional $20 Million for Further Development of Ebola Sudan and Marburg Vaccines

Submitted by Liz Powell on

WASHINGTON, D.C. and ROME, Italy, May 13, 2020 – The Sabin Vaccine Institute (Sabin) and its partner ReiThera Srl today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, has exercised the first two options, valued at $20 million, under the 2019 contract to advance the development of vaccines against Ebola Sudan and Marburg viruses through Phase 2 clinical trials.

Pages